Q1: 2026-04-29 Earnings Summary
EPS of $1.26 beats by $0.09
|
Revenue of
$10.28B
(2.63% Y/Y)
misses by $19.92M
GSK plc (GSK) Q1 2026 Earnings Call April 29, 2026 7:00 AM EDT
Company Participants
Luke Miels - CEO & Director
Nina Mojas - President of Global Product Strategy
Deborah Waterhouse - CEO of ViiV Healthcare & President of Global Health
Tony Wood - Chief Scientific Officer and Head of R&D
Julie Brown - CFO & Executive Director
Conference Call Participants
Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division
Zain Ebrahim - JPMorgan Chase & Co, Research Division
Graham Glyn Parry - Citigroup Inc., Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division
Sachin Jain - BofA Securities, Research Division
Matthew Weston - UBS Investment Bank, Research Division
Peter Verdult - BNP Paribas, Research Division
James Gordon - Barclays Bank PLC, Research Division
Sarita Kapila - Morgan Stanley, Research Division
Michael Leuchten
Simon Baker - Rothschild & Co Redburn, Research Division
Steve Scala - TD Cowen, Research Division
Emmanuel Papadakis - Deutsche Bank AG, Research Division
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Presentation
Operator
Ladies and gentlemen, a warm welcome to the GSK's Q1 '26 Results Call. I'm delighted to be joined today by Luke Miels, Nina Mojas, Deborah Waterhouse, Tony Wood and Julie Brown, and in our Q&A session will be joined by David Redfern. Today's call will last approximately 1 hour with a presentation taking around 30 minutes and the remaining time for your questions. [Operator Instructions] Before we start, please turn to Slide 3. This is the usual safe harbor statement. We will comment on our performance using constant exchange rates or CER, unless otherwise stated. I'll now hand over to Luke.
Luke Miels
CEO & Director
Thank you, and welcome, everyone. Q1 performance was strong. Sales were up 5% to more than GBP 7.6 billion. Growth was driven by Specialty Medicines, which were up 14%, with vaccines also contributing particularly through strong Shingrix sales. Core operating profit grew 10% and EPS was up 9%. Cash
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。